Current Global Pricing for Human Papillomavirus Vaccines Brings the Greatest Economic Benefits to Rich Countries
This article, published in Health Affairs, details an economic model that estimates the distribution of the economic surplus—the sum of all health and economic benefits of a vaccine, minus the costs of development, production, and distribution—among different country income groups and manufacturers for a cohort of twelve-year-old females given human papillomavirus (HPV) vaccine in 2012. The results showed that high-income countries gained the greatest economic value per vaccinated female. The authors conclude that subsidizing HPV vaccine prices in low- and middle-income countries could both reduce financial barriers to vaccine adoption and still allow high-income countries to retain their economic surpluses and manufacturers to retain their profits. ABSTRACT ONLY. (Learn how users in developing countries can gain free access to journal articles.)
Author: Herlihy N, Hutubessy R, Jit M
» Visit web page (English)
(Located at content.healthaffairs.org)
Citation: Herlihy N, Hutubessy R, Jit M. Current Global Pricing for Human Papillomavirus Vaccines Brings the Greatest Economic Benefits to Rich Countries. Health Affairs. 2016;35(2):227-234.
Resource types: Peer-reviewed journal
Diseases/vaccines: Human papillomavirus (HPV)